ADL5859 has been discovered by the world famous biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products, better known as Adolor Corporation, Pennsylvania, USA. Adolor is pronounced as a-do-lor which means Without Pain in Latin. The company submits investigational New Drug Application for Novel Delta Opioid Agonist Compound for the Management of Pains.

The company has recognized a series of novel, orally active Delta agonists that discriminatingly stimulate the Delta Opioid receptor, through the proprietary research platform based on cloned human Opioid receptors. ADL5859, the leading Delta candidate from Adolor Corporation has confirmed activity in numerous preclinical studies and is presently in the phase 1 clinical developments. On the basis of preclinical appraisal in animal models of human conditions, one would expect the Delta agonist exhibiting the effect in the inflammatory pain amongst other pain conditions.

Moreover, the Delta agonists are presumed to adapt other biological processes that may evident themselves in disease states or conditions including an overactive bladder as well as depressions. With no discriminating Delta agonists presently approved by the United States Food and Drugs Administration, Adolor Corporation’s Delta program is intensifying the leading edge of pain research.

The phase-1 clinical trial of ADL5859 is the novel orally bio-available delta Opioid receptor agonist. The phase-1 study is intended to explore the safety, permissibility as well as pharmacokinetics of the single dose of ADL5859 in the healthy volunteers. The company is now planning to conduct the multi dose safety studies as its next step towards the developments.